Cargando…

Exploring natural killer cell immunology as a therapeutic strategy in lung cancer

Cytotoxic immune cells are key in the control of tumor development and progression. Natural killer (NK) cells are the cytotoxic arm of the innate immune system with the capability to kill tumor cells and surveil tumor cell dissemination. As such, the interest in harnessing NK cells in tumor control...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hess, Jonas B., Sutherland, Kate D., Best, Sarah A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Lung Cancer and The Immune System
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264324/ https://www.ncbi.nlm.nih.gov/pubmed/34295678 http://dx.doi.org/10.21037/tlcr-20-765

Ejemplares similares

The effect of the sympathetic nervous system on splenic natural killer cell activity in mice administered the Lactobacillus pentosus strain S-PT84
por: Izumo, Takayuki, et al.
Publicado: (2013)

Lung cancer and the immune system—current controversies and future opportunities
por: Steinfort, Daniel P.
Publicado: (2021)

Precise navigation surgery of tumours in the lung in mouse models enabled by in situ fluorescence labelling with a killer-reporter adenovirus
por: Yano, Shuya, et al.
Publicado: (2015)

Potential applications of prognostic and immunological marker transmembrane serine proteinase 2 in prediction, prevention and personalized treatment of lung cancer
por: Mu, Bo, et al.
Publicado: (2022)

Emerging and multifaceted role of neutrophils in lung cancer
por: Aloe, Christian, et al.
Publicado: (2021)

Immunotherapy in oncogene addicted non-small cell lung cancer
por: McLean, Luke, et al.
Publicado: (2021)

Holding our breath: the promise of tissue-resident memory T cells in lung cancer
por: Marceaux, Claire, et al.
Publicado: (2021)

Integrated care for resected early stage lung cancer: innovations and exploring patient needs
por: Ho, Jan, et al.
Publicado: (2017)

B cells in lung cancer—not just a bystander cell: a literature review
por: Leong, Tracy L., et al.
Publicado: (2021)

Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer
por: Bozinovski, Steven, et al.
Publicado: (2021)

A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer
por: Akanda, Zarique Z., et al.
Publicado: (2021)

Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors
por: Rangamuwa, Kanishka, et al.
Publicado: (2021)

Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation
por: Rangamuwa, Kanishka, et al.
Publicado: (2021)

Management of Lung Cancer in the Patient with Interstitial Lung Disease
por: Frank, Angela J, et al.
Publicado: (2022)

Feasibility and acceptability of a community pharmacy referral service for suspected lung cancer symptoms
por: Holland-Hart, Daniella, et al.
Publicado: (2021)

Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial
por: Brain, Kate, et al.
Publicado: (2017)

Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial
por: Brain, Kate, et al.
Publicado: (2016)

Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency()
por: Hassan, Amel, et al.
Publicado: (2014)

A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients
por: Schlachtenberger, G., et al.
Publicado: (2021)

Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme
por: Lebrett, Mikey B, et al.
Publicado: (2020)

LDCT lung cancer screening in populations at different risk for lung cancer
por: Teles, Gustavo Borges da Silva, et al.
Publicado: (2020)

The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review
por: Miller, Alistair R., et al.
Publicado: (2021)

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
por: Lüchtenborg, Margreet, et al.
Publicado: (2014)

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
por: Field, J K, et al.
Publicado: (2016)

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data
por: Navani, Neal, et al.
Publicado: (2019)

Incidence of second and higher order smoking-related primary cancers following lung cancer: a population-based cohort study
por: Barclay, Matthew E, et al.
Publicado: (2019)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

Stage I and II Small-Cell Lung Cancer—New Challenge for Surgery
por: Doerr, Fabian, et al.
Publicado: (2022)

Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review
por: Hall, Helen, et al.
Publicado: (2022)

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
por: Lammers, Austin, et al.
Publicado: (2018)

Psychological outcomes of low-dose CT lung cancer screening in a multisite demonstration screening pilot: the Lung Screen Uptake Trial (LSUT)
por: Kummer, Sonja, et al.
Publicado: (2020)

What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
por: O'Dowd, Emma L, et al.
Publicado: (2015)

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
por: Hsu, Melinda L, et al.
Publicado: (2022)

White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer
por: Sibille, A., et al.
Publicado: (2021)

Prevalence and outcome of central airway obstruction in patients with lung cancer
por: Daneshvar, Cyrus, et al.
Publicado: (2019)

Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
por: Avancini, Alice, et al.
Publicado: (2019)

Evaluation of cardiovascular risk in a lung cancer screening cohort
por: Ruparel, Mamta, et al.
Publicado: (2019)

UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer
por: Baldwin, D R, et al.
Publicado: (2011)

Value of Precision Medicine in Advanced Non‐Small Cell Lung Cancer: Real‐World Outcomes Associated with the Use of Companion Diagnostics
por: John, Ani, et al.
Publicado: (2020)

Prevalence of pre-existing lung diseases and their association with income level among patients with lung cancer: a nationwide population-based case-control study in South Korea
por: Oh, Chang-Mo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oq62898vjlbqvb5lsr33tdr92g